Skip to main content
Top
Published in: BMC Pulmonary Medicine 1/2017

Open Access 01-12-2017 | Research article

Characteristics and longitudinal progression of chronic obstructive pulmonary disease in GOLD B patients

Authors: Philip J. Lawrence, Umme Kolsum, Vandana Gupta, Gavin Donaldson, Richa Singh, Bethan Barker, Leena George, Adam Webb, Anthony J. Brookes, Christopher Brightling, Jadwiga Wedzicha, Dave Singh

Published in: BMC Pulmonary Medicine | Issue 1/2017

Login to get access

Abstract

Background

The characteristics and natural history of GOLD B COPD patients are not well described. The clinical characteristics and natural history of GOLD B patients over 1 year in a multicentre cohort of COPD patients in the COPDMAP study were assessed. We aimed to identify the subgroup of patients who progressed to GOLD D (unstable GOLD B patients) and identify characteristics associated with progression.

Methods

Three hundred seventy COPD patients were assessed at baseline and 12 months thereafter. Demographics, lung function, health status, 6 min walk tests and levels of systemic inflammation were assessed. Students t tests and Mann Whitney-U tests were used.

Results

One hundred seven (28.9%) of patients were categorised as GOLD B at baseline. These GOLD B patients had similar FEV1 to GOLD A patients (66% predicted). More GOLD B patients were current smokers (p = 0.031), had chronic bronchitis (p = 0.0003) and cardiovascular comorbidities (p = 0.019) compared to GOLD A. At 12 months, 25.3% of GOLD B patients progressed to GOLD D. These patients who progressed (unstable patients) had worse health status and symptoms (SGRQ-C Total, 50.0 v 41.1, p = 0.019 and CAT, 21.0 v 14.0, p = 0.006) and lower FEV1 (60% v 69% p = 0.014) at baseline compared to stable patients who remained in GOLD B.

Conclusions

Unstable GOLD B patients who progressed to GOLD D had a higher level of symptoms at baseline. A high symptom burden may predict an increased likelihood of disease progression in GOLD B patients.
Appendix
Available only for authorised users
Literature
1.
go back to reference Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Available from: www.goldcopd.org. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Available from: www.​goldcopd.​org.
2.
go back to reference Agusti A, et al. Characteristics, stability and outcomes of the 2011 GOLD COPD groups in the ECLIPSE cohort. Eur Respir J. 2013;42(3):636–46.CrossRefPubMed Agusti A, et al. Characteristics, stability and outcomes of the 2011 GOLD COPD groups in the ECLIPSE cohort. Eur Respir J. 2013;42(3):636–46.CrossRefPubMed
3.
go back to reference Anto JM, et al. Epidemiology of chronic obstructive pulmonary disease. Eur Respir J. 2001;17(5):982–94.CrossRefPubMed Anto JM, et al. Epidemiology of chronic obstructive pulmonary disease. Eur Respir J. 2001;17(5):982–94.CrossRefPubMed
4.
go back to reference Vestbo J, et al. Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med. 2011;365(13):1184–92.CrossRefPubMed Vestbo J, et al. Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med. 2011;365(13):1184–92.CrossRefPubMed
5.
go back to reference Lange P, et al. Prediction of the clinical course of chronic obstructive pulmonary disease, using the new GOLD classification: a study of the general population. Am J Respir Crit Care Med. 2012;186(10):975–81.CrossRefPubMed Lange P, et al. Prediction of the clinical course of chronic obstructive pulmonary disease, using the new GOLD classification: a study of the general population. Am J Respir Crit Care Med. 2012;186(10):975–81.CrossRefPubMed
6.
go back to reference Quint JK, et al. Predictive accuracy of patient-reported exacerbation frequency in COPD. Eur Respir J. 2011;37(3):501–7.CrossRefPubMed Quint JK, et al. Predictive accuracy of patient-reported exacerbation frequency in COPD. Eur Respir J. 2011;37(3):501–7.CrossRefPubMed
7.
go back to reference Ramirez-Venegas A, et al. FEV1 decline in patients with chronic obstructive pulmonary disease associated with biomass exposure. Am J Respir Crit Care Med. 2014;190(9):996–1002.CrossRefPubMed Ramirez-Venegas A, et al. FEV1 decline in patients with chronic obstructive pulmonary disease associated with biomass exposure. Am J Respir Crit Care Med. 2014;190(9):996–1002.CrossRefPubMed
8.
go back to reference Jones PW, et al. Development and first validation of the COPD Assessment Test. Eur Respir J. 2009;34(3):648–54.CrossRefPubMed Jones PW, et al. Development and first validation of the COPD Assessment Test. Eur Respir J. 2009;34(3):648–54.CrossRefPubMed
9.
go back to reference Meguro M, et al. Development and validation of an improved, COPD-specific version of the St. George respiratory questionnaire. Chest. 2007;132(2):456–63.CrossRefPubMed Meguro M, et al. Development and validation of an improved, COPD-specific version of the St. George respiratory questionnaire. Chest. 2007;132(2):456–63.CrossRefPubMed
10.
11.
go back to reference Radolff LS. The CES-D scale: a self report depression scale for research in the general population. Appl Psychol Meas. 1977;1:385–401.CrossRef Radolff LS. The CES-D scale: a self report depression scale for research in the general population. Appl Psychol Meas. 1977;1:385–401.CrossRef
13.
go back to reference Wanger J, et al. Standardisation of the measurement of lung volumes. Eur Respir J. 2005;26(3):511–22.CrossRefPubMed Wanger J, et al. Standardisation of the measurement of lung volumes. Eur Respir J. 2005;26(3):511–22.CrossRefPubMed
14.
go back to reference Macintyre N, et al. Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J. 2005;26(4):720–35.CrossRefPubMed Macintyre N, et al. Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J. 2005;26(4):720–35.CrossRefPubMed
15.
go back to reference American Toracic Society (ATS) Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002;166:111–7. American Toracic Society (ATS) Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002;166:111–7.
16.
go back to reference Garcha DS, et al. Changes in prevalence and load of airway bacteria using quantitative PCR in stable and exacerbated COPD. Thorax. 2012;67(12):1075–80.CrossRefPubMed Garcha DS, et al. Changes in prevalence and load of airway bacteria using quantitative PCR in stable and exacerbated COPD. Thorax. 2012;67(12):1075–80.CrossRefPubMed
17.
go back to reference Lange P, Celli B, Agusti A. Lung-function trajectories and chronic obstructive pulmonary disease. N Engl J Med. 2015;373(16):1575.CrossRefPubMed Lange P, Celli B, Agusti A. Lung-function trajectories and chronic obstructive pulmonary disease. N Engl J Med. 2015;373(16):1575.CrossRefPubMed
18.
go back to reference Goossens LM, et al. Does the 2013 GOLD classification improve the ability to predict lung function decline, exacerbations and mortality: a post-hoc analysis of the 4-year UPLIFT trial. BMC Pulm Med. 2014;14:163.CrossRefPubMedPubMedCentral Goossens LM, et al. Does the 2013 GOLD classification improve the ability to predict lung function decline, exacerbations and mortality: a post-hoc analysis of the 4-year UPLIFT trial. BMC Pulm Med. 2014;14:163.CrossRefPubMedPubMedCentral
19.
go back to reference Kim J, et al. Lung function decline rates according to GOLD group in patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2015;10:1819–27.CrossRefPubMedPubMedCentral Kim J, et al. Lung function decline rates according to GOLD group in patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2015;10:1819–27.CrossRefPubMedPubMedCentral
20.
go back to reference Koskela J, Katajisto M, Kallio A, Kilpelainen M, Lindqvist A, Laitinen T. Individual FEV1 Trajectories Can Be Identified from a COPD Cohort. Copd. 2016;13(4):425–30. Koskela J, Katajisto M, Kallio A, Kilpelainen M, Lindqvist A, Laitinen T. Individual FEV1 Trajectories Can Be Identified from a COPD Cohort. Copd. 2016;13(4):425–30.
21.
go back to reference Boland MR, et al. Are GOLD ABCD groups better associated with health status and costs than GOLD 1234 grades? A cross-sectional study. Prim Care Respir J. 2014;23(1):30–7.CrossRefPubMed Boland MR, et al. Are GOLD ABCD groups better associated with health status and costs than GOLD 1234 grades? A cross-sectional study. Prim Care Respir J. 2014;23(1):30–7.CrossRefPubMed
22.
go back to reference Wesolowski S, Boros PW, Debowski T. Chronic obstructive pulmonary disease in Poland: distribution of patients according to the new GOLD 2011 classification. Cross-sectional survey. Pneumonol Alergol Pol. 2014;82(6):511–7.CrossRefPubMed Wesolowski S, Boros PW, Debowski T. Chronic obstructive pulmonary disease in Poland: distribution of patients according to the new GOLD 2011 classification. Cross-sectional survey. Pneumonol Alergol Pol. 2014;82(6):511–7.CrossRefPubMed
Metadata
Title
Characteristics and longitudinal progression of chronic obstructive pulmonary disease in GOLD B patients
Authors
Philip J. Lawrence
Umme Kolsum
Vandana Gupta
Gavin Donaldson
Richa Singh
Bethan Barker
Leena George
Adam Webb
Anthony J. Brookes
Christopher Brightling
Jadwiga Wedzicha
Dave Singh
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Pulmonary Medicine / Issue 1/2017
Electronic ISSN: 1471-2466
DOI
https://doi.org/10.1186/s12890-017-0384-8

Other articles of this Issue 1/2017

BMC Pulmonary Medicine 1/2017 Go to the issue